Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director | January 02, 2025 | January 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TriSalus Life Sciences, Inc.
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,040 |
Reported balance
After 2025-01-02 transaction · row 1
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 10,040 · Balance 10,040 F1: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the RSU Award in lieu of the 2025 cash Annual Board Service Retainer provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the RSU Award shall vest in equal quarterly installments on each of March 31, June 30, September 30 and December 31, 2025, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the RSU Award in lieu of the 2025 cash Annual Board Service Retainer provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the RSU Award shall vest in equal quarterly installments on each of March 31, June 30, September 30 and December 31, 2025, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 6, 2025 17:54 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 10,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000828 · form4-01062025_100110.xml · nonDerivative · entry 1 Hyveled Liselotte · CIK 0002015594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,040 F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the RSU Award in lieu of the 2025 cash Annual Board Service Retainer provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the RSU Award shall vest in equal quarterly installments on each of March 31, June 30, September 30 and December 31, 2025, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| August 13, 2024 Filed Aug 21, 2024 20:47 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001415889-24-021958 · form4-08222024_120815.xml · derivative · entry 1 Hyveled Liselotte · CIK 0002015594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 06, 2024 Filed May 7, 2024 17:56 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $9.62 | $0.00 |
DisclosureSEC source: 0001415889-24-012501 · form4-05072024_090508.xml · derivative · entry 1 Hyveled Liselotte · CIK 0002015594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-05-05 F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of May 6, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.